Saturday, October 31, 2026

GBP/EUR Bullish Momentum: 0.83% Up In The Last 5 Sessions

ViaNews Editorial Team

February 10, 2023

GBP/EUR Bullish Momentum: 0.83% Up In The Last 5 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 0.83% for the last 5 sessions. At 04:06 EST on Friday, 10 February, GBP/EUR (GBPEUR) is $1.13.

GBP/EUR's yearly highs and lows, it's 4.467% up from its 52-week low and 7.319% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.41%, a negative 0.02%, and a positive 0.36%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.51% (last week), 0.30% (last month), and 0.36% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd price analysis: bound in 50% and 61.8% fibo retracement ahead of German inflation. According to FXStreet on Wednesday, 8 February, "The EUR/USD pair is oscillating in an extremely narrow range around 1.0730 as investors are awaiting the release of the preliminary German inflation data for fresh impetus. "
  • Eur/usd forex signal: strong bullish bounce at 50-day SMA - 08 February 2023. According to DailyForex on Wednesday, 8 February, "My EUR/USD signal yesterday was not triggered, as the bullish price action took place below the support level which I had identified at $1.0766.", "In my analysis yesterday of the EUR/USD currency pair, I thought that we would see consolidation above the $1.07 handle during the London session."
  • Eur/usd stays pressured near 1.0700 as fed, ECB policymakers defend higher interest rates. According to FXStreet on Wednesday, 8 February, "While a slew of Fed and ECB policymakers spoke much about defending the restrictive monetary policy, Friday's upbeat US jobs report and activity data contrast with the comparatively lighter EU statistics to justify the Fed's hawkish stand, which in turn exerts downside pressure on the EUR/USD price.", "Additionally, a rebound in the US 10-year Treasury bond yields, after a downbeat start to Wednesday, joins Wall Street's negative closing to weigh on the EUR/USD prices."
  • Eur/usd pares weekly losses above 1.0700 amid fed vs. ECB battle, German inflation, EU economic forecasts eyed. According to FXStreet on Thursday, 9 February, "Even so, Federal Reserve (Fed) and US diplomats' defense of the higher interest rates seems to challenge the EUR/USD buyers amid an inactive session.", "Elsewhere, easing fears surrounding the US and China tension over the balloon shooting seems to have joined the lack of major negatives from elsewhere to underpin the mildly positive mood and propel the EUR/USD as the Euro traders await crucial data."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com